99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer

Journal article


Publication Details

Author(s): Schmidkonz C, Hollweg C, Beck M, Reinfelder J, Götz T, Sanders J, Schmidt D, Prante O, Bäuerle T, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P
Journal: Prostate
Publication year: 2018
Volume: 78
Journal issue: 1
Pages range: 54-63
ISSN: 0270-4137


Abstract


99m Tc-MIP-1404 (Progenics Pharmaceuticals, Inc., New York, NY) is a novel, SPECT-compatible 99m Tc-labeled PSMA inhibitor for the detection of prostate cancer. We present results of its clinical use in a cohort of 225 men with histologically confirmed prostate cancer referred for workup of biochemical relapse.From April 2013 to April 2017, 99m Tc-MIP1404-scintigraphy was performed in 225 patients for workup of PSA biochemical relapse of prostate cancer. Whole-body planar and SPECT/CT images of the lower abdomen and thorax were obtained 3-4 h p.i. of 710 ± 64 MBq 99m Tc-MIP-1404. Images were visually analyzed for presence and location of abnormal uptake. In addition, quantitative analysis of the SPECT/CT data was carried out on a subset of 125 patients. Follow-up reports of subsequent therapeutic interventions were available for 59% (139) of all patients.Tracer-positive lesions were detected in 77% (174/225) of all patients. Detections occurred at the area of local recurrence in the prostate in 25% of patients (or a total of 56), with metastases in lymph nodes in 47% (105), bone in 27% (60), lung in 5% (12), and other locations in 2% (4) of patients. Detection rates were 90% at PSA levels >=2 ng/mL and 54% below that threshold. Lesional SUVmax values were, on average, 32.2 ± 29.6 (0.8-142.2), and tumor-to-normal ratios 146.6 ± 160.5 (1.9-1482.4). The PSA level correlated significantly with total uptake of MIP-1404 in tumors (P < 0.001). Furthermore, total tumor uptake was significantly higher in patients with Gleason scores >=8 compared to those with Gleason scores <=7 (P < 0.05). In patients with androgen deprivation therapy, the detection rate was significantly higher compared to patients without androgen deprivation therapy (86% vs 71%, P < 0.001). Based on 99m Tc-MIP-1404-imaging and other information, an interdisciplinary tumor board review recommended changes to treatment plans in 74% (104/139) of those patients for whom the necessary documentation was available.SPECT/CT with 99m Tc-labeled MIP-1404 has a high probability in detecting PSMA-positive lesions in patients with elevated PSA. Statistical analysis disclosed significant relationship between quantitative 99m Tc-MIP-1404 uptake, PSA level, and Gleason score.



FAU Authors / FAU Editors

Bäuerle, Tobias Prof. Dr.
Professur für Multimodale Bildgebung in der präklinischen Forschung
Beck, Michael
Lehrstuhl für Klinische Nuklearmedizin
Goebell, Peter Prof. Dr.
Urologische Klinik
Götz, Theresa
Kuwert, Torsten Prof. Dr.
Lehrstuhl für Informatik 5 (Mustererkennung)
Lehrstuhl für Klinische Nuklearmedizin
Prante, Olaf Prof. Dr.
Professur für Molekulare Bildgebung und Radiochemie
Reinfelder, Julia Dr. med.
Nuklearmedizinische Klinik
Ritt, Philipp Dr.-Ing.
Nuklearmedizinische Klinik
Sanders, James
Lehrstuhl für Informatik 5 (Mustererkennung)
Schmidkonz, Christian Dr.
Medizinische Fakultät
Schmidt, Daniela PD Dr.
Medizinische Fakultät
Uder, Michael Prof. Dr.
Lehrstuhl für Diagnostische Radiologie
Wullich, Bernd Prof. Dr.
Lehrstuhl für Urologie


How to cite

APA:
Schmidkonz, C., Hollweg, C., Beck, M., Reinfelder, J., Götz, T., Sanders, J.,... Ritt, P. (2018). 99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer. Prostate, 78(1), 54-63. https://dx.doi.org/10.1002/pros.23444

MLA:
Schmidkonz, Christian, et al. "99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer." Prostate 78.1 (2018): 54-63.

BibTeX: 

Last updated on 2019-18-07 at 07:30